Your cart is empty.
Your cart is empty.
Novera supplies healing and regenerative peptide compounds to qualified researchers, laboratories, and scientific institutions. All materials in this category are sourced from USA GMP-certified manufacturers, verified by Certificate of Analysis (COA) for identity and purity, and catalogued exclusively for use in controlled experimental settings. This page provides molecular profiles, research classification data, and procurement information for compounds studied in growth factor receptor activation assays, extracellular matrix (ECM) remodeling pathway models, angiogenesis signaling research, and cellular proliferation and migration marker profiling in wound biology and regenerative cell line systems.
Erythropoietin-derived peptide with anti-inflammatory and neuroprotective properties. 10mg vial.
Erythropoietin-derived peptide with anti-inflammatory and neuroprotective properties. 14mg vial.
Relaxin-derived analogue with anti-fibrotic and cardioprotective peptide properties. 5mg vial.
Synthetic pentadecapeptide promoting tissue healing, gut repair, and joint recovery. 5mg vial.
Synthetic pentadecapeptide promoting tissue healing, gut repair, and joint recovery. 10mg vial.
Synthetic pentadecapeptide promoting tissue healing, gut repair, and joint recovery. 15mg vial.
Synthetic pentadecapeptide promoting tissue healing, gut repair, and joint recovery. 20mg vial.
Synthetic pentadecapeptide for tissue healing, gut repair, and joint recovery. 30 tabs, 500mcg each.
Cartilage peptide bioregulator supporting connective tissue repair and joint health. 50mg vial.
Bronchial peptide bioregulator supporting lung tissue function and respiratory health. 50mg vial.
Copper-binding tripeptide promoting skin regeneration, wound healing, and anti-aging. 50mg vial.
We work with leading pharmaceutical brands specializing in Healing & Regenerative Peptides medications, selected for their clinical reliability, regulatory compliance, and consistent treatment outcomes.
This category is organized into three subcategories, each addressing a distinct domain of tissue repair and regenerative signaling research:
BPC-157 — 5 mg
| Sequence | Pentadecapeptide: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 AA) |
| Molecular Weight | 1,419.56 Da |
| Format | Lyophilized powder, 5 mg vial |
| Purity | >=98% (HPLC verified, COA on file) |
| Research Classification | Cytoprotective signaling peptide derived from gastric juice protein BPC; studied in VEGFR2, EGFR, and FAK receptor interaction assays, NO-synthase pathway activation models, fibroblast and endothelial cell migration and proliferation marker profiling, and ECM remodeling research in wound biology and tissue repair cell systems |
Thymosin Beta-4 (TB-500) — 10 mg
| Sequence | 43-residue G-actin sequestering peptide: Ac-SDKPDMAEIEKFDKSKLKKTETTLKQEYDTLEKEAKKNNE-OH |
| Molecular Weight | 4,963.50 Da |
| Format | Lyophilized powder, 10 mg vial |
| Purity | >=98% (HPLC verified, COA on file) |
| Research Classification | G-actin sequestering thymic peptide; studied in actin polymerization dynamics, WASP/N-WASP interaction models, keratinocyte and endothelial cell migration assays, angiogenesis pathway marker profiling, and anti-inflammatory cytokine regulation research in wound healing cell systems |
GHK-Cu (Copper Peptide) — 50 mg
| Sequence | Copper-binding tripeptide complex: Gly-His-Lys · Cu(2+) |
| Molecular Weight | 403.95 Da (copper complex) |
| Format | Lyophilized powder, 50 mg unit |
| Purity | >=98% (HPLC verified, COA on file) |
| Research Classification | Copper-binding tripeptide; studied in fibroblast collagen synthesis pathway assays, TGF-beta receptor and SPARC interaction models, MMP activity profiling in ECM remodeling research, and Nrf2-mediated antioxidant signaling in wound repair cell biology |
PDGF-BB Peptide Fragment — 0.5 mg
| Sequence | Synthetic peptide corresponding to PDGF-BB receptor-binding loop region; sequence confirmed by MS — consult COA for lot-specific details |
| Molecular Weight | ~1,200-1,600 Da (fragment-dependent) |
| Format | Lyophilized powder, 0.5 mg vial |
| Purity | >=95% (HPLC verified, COA on file) |
| Research Classification | PDGF-BB derived receptor-binding peptide fragment; studied in PDGFR-beta binding competition assays, pericyte and fibroblast activation marker research, PI3K-Akt and MAPK downstream signaling cascade profiling, and angiogenesis co-factor pathway investigation in vascular biology research |
BPC-157 has the most extensively documented growth factor receptor interaction profile in the published wound biology literature. Studies have characterized its associations with VEGFR2 phosphorylation in endothelial cell models, EGFR activation in epithelial cell line systems, and focal adhesion kinase (FAK) signaling dynamics in fibroblast scratch assay models. Published assays use receptor phosphorylation Western blot, transwell migration quantification, and scratch wound closure rate measurement as primary endpoints. PDGF-BB peptide fragments have been studied in parallel PDGFR-beta binding competition and pericyte activation assays. All migration and proliferation data are generated in defined in vitro cell systems under controlled laboratory conditions.
Thymosin Beta-4’s G-actin sequestering mechanism positions it as the primary experimental tool for studying actin dynamics in wound-associated cell migration research. Published studies have used primary keratinocyte and HaCaT cell line models to characterize G-actin/F-actin ratio dynamics by DNase I inhibition assay and fluorescence microscopy, WASP/N-WASP interaction profiling in actin nucleation pathway research, and lamellipodia formation dynamics in live-cell TIRF microscopy under defined TB-500 concentration conditions. TB-500 has also been studied in endothelial cell tubulogenesis assays using Matrigel-based angiogenesis models, with tube length and branching point quantification as primary angiogenic marker endpoints.
GHK-Cu is among the most studied compounds in published literature examining collagen synthesis and ECM remodeling pathway dynamics in fibroblast and dermal cell systems. Published assays have profiled procollagen type I and III N-propeptide (PINP, PIIINP) expression in primary fibroblast and NIH3T3 cell models using ELISA-based quantification, TGF-beta receptor downstream signaling dynamics (Smad2/3 phosphorylation, CTGF expression), and matrix metalloproteinase activity (MMP-1, MMP-2, MMP-9) by gelatin zymography. These assays characterize peptide interactions with ECM remodeling pathway components at defined molecular nodes in vitro.
Multiple compounds in this category appear in published angiogenesis research. VEGFR2 phosphorylation assays using HUVEC and HMEC-1 endothelial cell line models represent the primary functional endpoint for angiogenic pathway investigation, alongside tube formation assays in Matrigel matrix systems and endothelial cell proliferation quantification by BrdU incorporation or Ki-67 immunostaining. BPC-157 and TB-500 have both been studied in these endothelial model systems, with published studies characterizing their effects on VEGF expression marker dynamics and endothelial migration rate in scratch assays. These in vitro assays characterize angiogenesis-associated signaling pathway behavior without reference to tissue vascularization outcomes in organisms.
Researchers designing studies in wound biology, ECM remodeling, or angiogenesis pathway investigation typically evaluate compound selection based on the specific signaling node under investigation — growth factor receptor interaction (BPC-157, PDGF-BB fragment), actin cytoskeletal dynamics (TB-500), ECM synthesis and remodeling (GHK-Cu), or endothelial angiogenesis pathway profiling (BPC-157, TB-500) — molecular stability in serum-containing fibroblast and endothelial cell culture media, and COA-verified purity with endotoxin data, particularly relevant for primary cell and organotypic culture applications.
Novera provides complete product specifications for each compound including molecular weight, sequence, storage conditions, and available presentation formats. Researchers are encouraged to review compound data sheets and cross-reference with primary wound biology and regenerative signaling literature before finalizing protocols. Novera does not provide experimental design guidance, dosing parameters, or outcome interpretation.
Institutional procurement offices and principal investigators with multi-compound or volume supply requirements are invited to contact Novera’s research supply team to confirm batch availability, lot consistency documentation, and GMP certification status for each referenced material.
All compounds in this category are procured from USA-based GMP-certified manufacturing facilities. Standard quality documentation and protocols include:
Novera does not supply compounds for human or veterinary administration. All purchase documentation classifies materials as research and laboratory use only. Institutional and bulk procurement arrangements are available subject to qualification review.
In cell biology and regenerative medicine research literature, healing and regenerative peptides refer to amino acid sequences studied for their interactions with signaling pathways associated with cellular repair, tissue remodeling, and vascular biology at the molecular level. This category encompasses cytoprotective and growth factor receptor-interacting sequences such as BPC-157, studied in VEGFR2 and FAK pathway assays; actin-regulatory peptides such as Thymosin Beta-4, studied in cytoskeletal dynamics and angiogenesis models; ECM-modulating sequences such as GHK-Cu, studied in collagen synthesis and MMP activity research; and growth factor subunit fragments studied in receptor binding competition and downstream signaling cascade models.
Classification within this category is based on documented molecular interaction profiles in published cell biology and regenerative research literature. No compound is represented as a wound healing agent, tissue repair treatment, or regenerative therapy of any kind. All materials are supplied as experimental research tools for mechanistic investigation in qualified laboratory settings by trained scientific personnel operating under appropriate institutional frameworks.
Cartilage peptide bioregulator supporting connective tissue repair and joint health. 50mg vial.
Healing peptide blend of BPC-157 and TB500 for accelerated tissue and tendon repair. 5mg each.
Bronchial peptide bioregulator supporting lung tissue function and respiratory health. 50mg vial.
BPC-157 and TB-500 both appear in wound biology literature, but operate through mechanistically distinct pathways that enable orthogonal endpoint design. BPC-157’s primary published mechanism centers on growth factor receptor phosphorylation (VEGFR2, EGFR, FAK) and NO-synthase pathway activation, making receptor phosphorylation Western blot and nitric oxide quantification (Griess reagent or DAF-FM fluorescence) the most mechanistically informative endpoints. TB-500’s primary mechanism involves G-actin sequestration and actin polymerization dynamics, making DNase I inhibition-based G/F-actin ratio quantification and lamellipodia imaging the most specific endpoints. Researchers designing multi-compound assays can use these orthogonal endpoints simultaneously to track both signaling axes without cross-pathway interference.
Novera supplies GHK-Cu in the copper-complexed form as standard, which is the form studied in the majority of published collagen synthesis and TGF-beta pathway research. The copper moiety is integral to GHK-Cu’s documented antioxidant and Nrf2 pathway interaction profile; the free GHK tripeptide has a separate published interaction profile centered primarily on TGF-beta receptor and SPARC binding without the copper-associated antioxidant activity. For assays specifically targeting TGF-beta/Smad2-3 pathway dynamics, both forms have been used in published research, but the copper-complexed form is the standard reference compound in this literature. Researchers requiring the free GHK tripeptide for metal-free control conditions should contact Novera’s supply team to confirm availability.
Matrigel tube formation assays for endothelial cell tubulogenesis are a standard model for characterizing TB-500’s angiogenic pathway interaction. Published protocols typically use growth factor-reduced Matrigel at 8-10 mg/mL polymerized at 37 degrees Celsius, seeded with 1-2 x 10(4) HUVEC or HMEC-1 cells per well in a 96-well format, with tube formation assessed at 4-8 hours by brightfield microscopy. Primary quantitative endpoints include total tube length, number of branching points, and number of enclosed loops measured by ImageJ or automated analysis software. Researchers should include a VEGF-A positive control at defined concentration and vehicle-matched negative control conditions to validate assay sensitivity before introducing experimental compound conditions.
Researchers designing multi-compound wound healing assay panels typically require matched lot documentation across compounds to ensure consistent quality control references for the complete experimental series. Novera accommodates multi-compound institutional procurement with combined COA packages, allowing researchers to document purity, endotoxin levels, and lot identifiers for BPC-157, TB-500, GHK-Cu, and PDGF-BB fragment as a unified supply record. Researchers should specify assay application type — primary cell, immortalized cell line, or organotypic model — when requesting supply to enable the supply team to recommend appropriate endotoxin testing documentation levels for each compound in the panel.
All products are sold for Research Use Only. To continue you confirm that you are qualified research professional aged 21 or older.